Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-DE-24-002 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit developmental/exploratory research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC). (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 7, 2023 Category: Research Source Type: funding
Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DE-24-001 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC). (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 7, 2023 Category: Research Source Type: funding
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-086 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 18, 2022 Category: Research Source Type: funding
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-085 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 18, 2022 Category: Research Source Type: funding
Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DE-22-003 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to solicit research to better understand the epidemiology and biology of oral human papillomavirus (HPV) infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 29, 2021 Category: Research Source Type: funding
Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-DE-22-004 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to solicit research to better understand the epidemiology and biology of oral human papillomavirus (HPV) infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 28, 2021 Category: Research Source Type: funding
Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)
Funding Opportunity PAR-20-034 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control appli...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 18, 2019 Category: Research Source Type: funding
Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 - Clinical Trial Not Allowed)
Funding Opportunity PA-18-874 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/ developmental research on biologic factors that mediate the differences in prevalence and severity of Dental, Oral, and Craniofacial (DOC)-related diseases and conditions in oral health disparities populations. It is long recognized that certain racial and ethnic populations suffer an increased burden of DOC diseases and conditions, such as oral/oropharyngeal cancers, early childhood caries (ECC), dental caries, and periodontitis. For each of these diseases, s...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 25, 2018 Category: Research Source Type: funding
Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)
Funding Opportunity PAR-18-681 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control appli...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 27, 2018 Category: Research Source Type: funding
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)
Funding Opportunity PA-18-014 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type;...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 3, 2017 Category: Research Source Type: funding
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01 Clinical Trial Optional)
Funding Opportunity PA-18-004 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or gr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 3, 2017 Category: Research Source Type: funding
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21)
Funding Opportunity ID: 290354 Opportunity Number: PA-17-061 Opportunity Title: Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: EducationHealthCategory Explanation: CFDA Number(s): 93.395Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public h...
Source: Grants.gov - November 29, 2016 Category: Research Tags: Education Health Source Type: funding
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01)
Funding Opportunity PA-17-060 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or gr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 28, 2016 Category: Research Source Type: funding
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21)
Funding Opportunity PA-17-061 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type;...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 28, 2016 Category: Research Source Type: funding
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01)
Funding Opportunity ID: 290372 Opportunity Number: PA-17-060 Opportunity Title: Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: EducationHealthCategory Explanation: CFDA Number(s): 93.395Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public h...
Source: Grants.gov - November 28, 2016 Category: Research Tags: Education Health Source Type: funding
